YouTube’s Dr. Dan on GLP-1s: The Science, Myths, and Future of Weight Loss Medications P1

Resources for the Community:

________________________________________________________________

https://linktr.ee/theplussidezpodcast

Ro - Telehealth for GLP1 weight management

https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55

______________________________________________________________________

This isn’t medical advice — always talk to your doctor before making any health decisions.

In this episode, we sit down with Dr. Dan, a pharmacist and expert in Obesity Medicine, to unpack the science and future of the new generation of weight loss medications.

We unpack the basics, like what is insulin resistance? Dr. Dan explains how GLP-1 medications effectively treat this core metabolic dysfunction and why their multi-hormonal action provides superior, sustained results compared to older weight loss drugs. He also delves into the age-related changes in metabolism that make weight management challenging.

Dr Dan tackles some obesity and GLP1 myths with us as well. He debunks the popular and potentially harmful myth of "cycling GLP-1s" to prevent "receptor damage,". He emphaszies how obesity is a chronic disease that needs consistent treatment. Following this, we explore real-world strategies for weight loss maintenance, discussing the different treatment scenarios he sees in his practice.

Finally, we look ahead to the future: understanding the next wave of pipeline GLP-1s and current studies on higher doses. Dr. Dan discusses combined therapies as patients get further into their health and wellness journey.

Community Guest:

Lorri

@Glpjourneyinreview

Professional Guest:

Dr. Dan

@theofficialdrdan

Dr. Dan's Empowerment Hub - https://drdans-empowermenthub.mn.co/share/KQA8wVMb6pOc5R79?utm_source=manual

______________________________________________________________________

⭐️Mounjaro Stanley⭐️

griffintumblerco.Etsy.com

Use code PODCAST10 for $ OFF

______________________________________________________________________